Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family
Published 2008 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 118, Issue 11, Pages 3574-3581
Publisher
American Society for Clinical Investigation
Online
2008-10-31
DOI
10.1172/jci36049
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells Is a Primary Target for Therapy with Tyrosine Kinase Inhibitors
- (2015) Toshio Kuwai et al. NEOPLASIA
- Modification of the Primary Tumor Microenvironment by Transforming Growth Factor α-Epidermal Growth Factor Receptor Signaling Promotes Metastasis in an Orthotopic Colon Cancer Model
- (2008) Takamitsu Sasaki et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
- (2008) H. J. Burstein et al. ANNALS OF ONCOLOGY
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
- (2008) Zhang Weihua et al. CANCER CELL
- Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma
- (2008) B. Zhang et al. CANCER RESEARCH
- Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
- (2008) Shigeki Higashiyama et al. CANCER SCIENCE
- c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling
- (2008) Mrudula Donepudi et al. CELLULAR SIGNALLING
- Polarized immune responses differentially regulate cancer development
- (2008) Magnus Johansson et al. IMMUNOLOGICAL REVIEWS
- IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
- (2008) Bin Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
- (2008) David F. Stern JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone
- (2008) S. R. Chinni et al. MOLECULAR CANCER RESEARCH
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenes and Cancer
- (2008) Carlo M. Croce NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion
- (2008) P Arora et al. ONCOGENE
- Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations
- (2008) C Q Cai et al. ONCOGENE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
- Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes
- (2008) Z Cai et al. ONCOGENE
- Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
- (2007) N. Rocks et al. BIOCHIMIE
- The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation
- (2007) Saveria Pastore et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More